Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 23Thoracic 15Breast 10Head & Neck 6Genitourinary 4Sarcoma 3Gynecologic 3Endocrine 3Tumor-Agnostic 2NET 2Dermatologic 2CNS 2Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liquid Biopsy × NET × Clear all
NCT05255133 2025-01-06

Liquid-NET

Universiteit Antwerpen

Phase NA Completed
22 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05268952 2022-03-07

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

University Hospital, Antwerp

Phase NA Unknown
100 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡